These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38697314)

  • 1. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 3. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
    J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
    Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
    Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.
    Yin W; Xu T; Ding H; Zhang J; Bodenko V; Tretyakova MS; Belousov MV; Liu Y; Oroujeni M; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2023 Mar; 355():515-527. PubMed ID: 36773960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
    Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
    Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins.
    Brandl F; Merten H; Zimmermann M; Béhé M; Zangemeister-Wittke U; Plückthun A
    J Control Release; 2019 Aug; 307():379-392. PubMed ID: 31252038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy.
    Yin W; Xu T; Altai M; Oroujeni M; Zhang J; Vorobyeva A; Vorontsova O; Vtorushin SV; Tolmachev V; Gräslund T; Orlova A
    Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds.
    Zhou Y; Li J; Gao G; Li Y; Zhang C
    Heliyon; 2024 Jan; 10(2):e24340. PubMed ID: 38293540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2.
    Xu T; Zhang J; Oroujeni M; Tretyakova MS; Bodenko V; Belousov MV; Orlova A; Tolmachev V; Vorobyeva A; Gräslund T
    Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-binding domain extends half-life of glucagon-like peptide-1.
    Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
    Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
    Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
    Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life.
    Brandl F; Busslinger S; Zangemeister-Wittke U; Plückthun A
    J Control Release; 2020 Nov; 327():186-197. PubMed ID: 32768630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.